Vaxart has filed for an upcoming stock offering with the number of shares yet to be announced. Vaxart is developing oral vaccines based on it proprietary oral recombinant vaccine technology. The company currently trades on the Nasdaq Capital Market under the symbol "VXRT."

The company currently has 4 candidates in its pipeline. The most advanced candidates are vaccines for norovirus and influenza. The norovirus vaccine is in Ph I trials and the influenza vaccine is in Ph II. In addition to providing a more acceptable administration route, the company believes that it's flu vaccine could be more efficacious than current vaccines.

As of this writing, the shares are 78% below their 52 week high. The shares opened 10% below previous close.